Search results
There is a page named "Ofatumumab" on Wikipedia
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved...28 KB (2,001 words) - 02:34, 16 July 2024
Cancer immunotherapy (section Ofatumumab)CD20 protein, ofatumumab binds to a separate, small loop. This may explain their different characteristics. Compared to rituximab, ofatumumab induces complement-dependent...89 KB (10,338 words) - 14:21, 16 July 2024
this disease, other anti-CD20 drugs such as ocrelizumab, veltuzumab, and ofatumumab have been explored as potential treatments. Key companies in Pemphigus...17 KB (1,943 words) - 07:31, 29 July 2024
22-0.25 Zeposia Ozanimod [better source needed] Oral 0.18-0.24 Kesimpta Ofatumumab Subcutaneous 70% 0.09-0.14 Mavenclad Cladribine Oral 70% 0.1-0.14 Lemtrada...170 KB (18,095 words) - 13:49, 16 August 2024- GlaxoSmithKline decided to exit oncology, which impacted co-development of ofatumumab, an oncology-directed product. In tandem with the sale of the plant, the...26 KB (1,906 words) - 04:10, 19 June 2024
developed: ocrelizumab, humanized (90%-95% human) B cell-depleting agent. ofatumumab (HuMax-CD20) a fully human B cell-depleting agent. Third-generation anti-CD20s...59 KB (5,329 words) - 06:45, 23 August 2024
company acquired the remaining rights to the CD20 monoclonal antibody Ofatumumab from GlaxoSmithKline for up to $1 billion. In October the company acquired...144 KB (12,103 words) - 22:04, 23 August 2024
ibrutinib down-modulates the expression of CD20 (target of rituximab/ofatumumab) by targeting the CXCR4/SDF1 axis. Together, these data are consistent...29 KB (2,605 words) - 21:22, 16 August 2024
CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active...26 KB (2,953 words) - 22:19, 25 June 2024- Ocusert Pilo Ocusulf odanacatib (USAN) odronextamab (INN) odulimomab (INN) ofatumumab (INN) oglufanide disodium (USAN) Ogsiveo Ohtuvayre Ojemda Ojjaara olaflur...7 KB (366 words) - 22:49, 14 August 2024
Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal...49 KB (4,964 words) - 04:02, 9 August 2024- Ocrelizumab L04AG09 Emapalumab L04AG10 Inebilizumab L04AG11 Anifrolumab L04AG12 Ofatumumab L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab L04AG16 Rozanolixizumab...3 KB (367 words) - 15:37, 25 January 2024
July 2020. Retrieved 23 January 2020. "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients...136 KB (4,020 words) - 07:14, 15 August 2024- Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid:...12 KB (760 words) - 03:40, 23 July 2024
- Cedelizumab Emapalumab Fontolizumab Inebilizumab Maslimomab Morolimumab Ofatumumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox...7 KB (299 words) - 13:45, 27 April 2024
3-kinase), as well as monoclonal antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab). Notably, some of the effects...73 KB (7,597 words) - 17:09, 3 August 2024
monoclonal antibody, has been approved for some indications. Ocrelizumab, ofatumumab, and "third-generation" anti-CD20 monoclonals are in development.[citation...31 KB (2,727 words) - 21:26, 26 January 2024- Sitravatinib L01EX27 Capivasertib QL01EX90 Toceranib L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab...12 KB (877 words) - 15:36, 25 January 2024
- abnormal temperature increases, headache, abdominal pain, and vomiting. Ofatumumab IV Anti-CD20 antibody. Chronic lymphocytic leukaemia Neutropenia, pneumonia...52 KB (708 words) - 00:21, 11 April 2024
completed pivotal phase III trial DUO comparing duvelisib monotherapy with ofatumumab led to its approval for CLL/SLL An extension trial to DUO was completed...45 KB (5,359 words) - 22:07, 19 July 2024
- English Wikipedia has an article on: ofatumumab Wikipedia From -tum- (“tumor”) + -umab (“human monoclonal antibody”). (This etymology is missing or incomplete
- gov/m/pubmed/21531096/?i=50&from=Opsoclonus-myoclonus%20syndrome BRIEF REPORT: Ofatumumab for a Rituximab-Allergic Child With Chronic-Relapsing Paraneoplastic